Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

Closed Date11/2011

General Information

Websiteaerovance.com
CategoryBioTech
Employees
Founded2004
Descriptionrespiratory, allergic medicines

Offices

United States
Berkeley,
San Francisco Bay Area
CA, USA

People

Investor

Funding

TOTAL $98.5M
FUNDING TOTAL $98.5M
Series C, 3/2007
Clarus Ventures
Lehman Brothers
Alta Partners
Apax Partners
NGN Capital
Burrill & Company
$60M
Venture Round, 4/2009
ProQuest Investments
BB Biotech Ventures
Alta Partners
Apax Partners
Burrill & Company
Clarus Ventures
NGN Capital
Lehman Brothers
$38M
Partial Close, 3/2011
$500k
DEBT TOTAL $22M
Debt, 3/2008
Comerica Bank
SVB Financial Group
$20M
Debt, 9/2010
$2M

Tags

Aerovance Closed down November 17, 2011

Aerovance

Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing breakthrough medicines for respiratory and allergic diseases. The company maintains a solid intellectual property position with its strong portfolio of novel therapeutic candidates now in clinical development and several pre-clinical programs. The two lead products are human recombinant proteins: Aerovantâ„¢, an IL-4 and -13 receptor antagonist which is in Phase IIa studies for asthma and Aerodermâ„¢, a PEGylated IL-4 and IL-13 receptor antagonist in pre-clinical studies for eczema.

Recent Milestones

Videos

Screenshots

Sources

  1. Aerovance, asthma treatment company, finishes raising $60M (venturebeat.com) [edit]
  2. Aerovance Secures $20 Million in Debt Financing (prnewswire.com) [edit]
  3. Aerovance inhales $38M for asthma drugs (venturebeat.com) [edit]
  4. SEC (sec.gov) [edit]
  5. SEC (sec.gov) [edit]
Edit This Page
Last Edited 1/30/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy